Akari Therapeutics Plc Sponsored ADR AKTX 深 滬
等待開盤 06-25 09:30:00 美东时间
10.755
-1.035
-8.78%
華盛通- 最 高11.90
- 今 開11.90
- 成交量 2.87万股
- 最 低 10.55
- 昨 收 11.79
- 總市值 1693.20万
- 52周最高 49.60
- 市盈率 靜 --
- 換手率 1.82%
- 52周最低 3.015
- 委 比 -29.24%
- 總股本 157.43万
- 歷史最高 95200.00
- 量 比 0.29
- 振 幅 11.45%
- 歷史最低 4.804
- 每 手 1
- 風險率 14.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026
Akari Therapeutics highlights the growing importance of novel ADC payloads and its ASCO data on KRAS-driven cancers. CEO Abizer Gaslightwala discusses the shift to "ADC 2.0" with differentiated payloads, addressing resistance challenges and expanding therapeutic potential. Akari's PH1 spliceosome-modulating payload platform shows promise in KRAS-mutated pancreatic cancer models and is expected to enter Phase 1 trials by mid-2027. The company emph...
06-04 13:30
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers PRF Technologies (NASDAQ:PRFX) stock rose 231.0% to $4.54 during Frida...
05-30 01:06
3 Penny Stocks to Watch Now, 5/26/26
Akari Therapeutics ($AKTX), QTREX Quantum Limited ($QTEX), and LEIFRAS Co. Limi...
05-26 22:40
Akari Therapeutics Stock Jumps On Promising Preclinical Data
Akari Therapeutics shares are surging after preclinical data showed AKTX‑101 synergized with KRAS inhibition in pancreatic cancer models.
05-22 23:17
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Akari Therapeutics (NASDAQ:AKTX) stock increased by 40.3% to $7.21 dur...
05-22 05:06
Akari Therapeutics shares are trading higher after the company announced a $5 million private placement.
Akari Therapeutics shares are trading higher after the company announced a $5 m...
05-21 23:32
Akari Therapeutics Reports Breakthrough Preclinical Data Demonstrating Synergistic Activity of AKTX-101 with KRAS Inhibition in KRAS-Mutated Pancreatic Cancer Models
Akari Therapeutics' AKTX-101, a TROP2-targeting ADC with a novel RNA spliceosome-modulating payload PH1, demonstrates synergistic cytotoxic activity when combined with KRAS inhibitors in KRAS G12D and G12C-driven pancreatic cancer models. The study highlights AKTX-101's potential to enhance KRAS inhibitor efficacy, unlike conventional ADCs, by targeting pre-mRNA transcripts for degradation. These findings support RNA splicing modulation as a prom...
05-21 21:01
Akari Therapeutics announces $5.5M private placement offering
Akari Therapeutics (AKTX) announced on Thursday the pricing of a private placement financing round, expecting to raise an aggregate of approximately $5.5M in gross proceeds. With these funds, the comp...
05-21 20:48
Akari Therapeutics Commences $5.5M Private Placement
Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the successful pricing of a private
05-21 20:34
Akari Therapeutics to Present at A.G.P.’s Annual Healthcare Company Showcase
Akari Therapeutics' CEO, Abizer Gaslightwala, will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026. The discussion will focus on the company’s ADC pipeline, including its PH1 RNA splicing modulator payload platform and lead TROP2-targeting ADC program, AKTX-101. Akari is developing next-generation ADCs with PH1, a novel payload targeting RNA splicing in cancer cells. AKTX-101 has shown significant act...
05-18 13:05
